All In Biotech

Drug Trial Radar · NCT03887455

A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease

Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,906 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,906

Actual

Start

Mar 27, 2019

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Eisai Inc.Eisai
Sponsor type
Industry
Collaborators
Biogen
First posted
Mar 25, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determining the superiority of lecanemab compared with placebo on the change from baseline in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) at 18 months of treatment in the Core Study. This study will also evaluate the long-term safety and tolerability of lecanemab in participants with EAD in the Extension Phase and whether the long-term effects of lecanemab as measured by the CDR-SB at the end of the Core Study is maintained over time in the Extension Phase. Extension Phase Part B will continue dosing with lecanemab in countries where lecanemab may not be commercially available.

Conditions

  • Early Alzheimer's Disease

Interventions

  • Lecanemab IVDrug

    Administered as IV infusion.

  • PlaceboDrug

    Biweekly (once every 2 weeks) administered as IVinfusion.

  • Lecanemab SCDrug

    Administered weekly as a SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Core Study: Change from Baseline in the CDR-SB at 18 MonthsTime frame: Baseline, 18 months
  2. Extension Phase: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)Time frame: From first dose of study drug up to approximately 51 months (including 3 months follow up) for the extension phase
  3. Extension Phase: Change from Core Study Baseline in CDR-SBTime frame: Baseline up to Month 66
  4. Extension Phase Part B: Number of Participants Exposed to LecanemabTime frame: From 48th month in extension phase part A to the end of extension phase part B (up to 24 months)

Locations

247 sites in 14 countries. Site status is shown where the registry gives one.

  • Banner Alzheimer's Institute- Clinical Trials Department

    Phoenix, Arizona

  • Banner Sun Health Research

    Sun City, Arizona

  • Neurological Associates of Tucson dba Center for Neurosciences

    Tucson, Arizona

  • Neurology Center of North Orange County

    Fullerton, California

  • Irvine Clinical Research

    Irvine, California

  • University of California - Los Angeles

    Los Angeles, California

  • Pacific Neuroscience Medical Group

    Oxnard, California

  • Stanford University Medical Center

    Palo Alto, California

  • Pacific Research Network, Inc

    San Diego, California

  • Sharp Neurocognitive Research Center

    San Diego, California

  • UCSF Memory and Aging Center

    San Francisco, California

  • Apex Research Institute

    Santa Ana, California

  • St Joseph Heritage Healthcare

    Santa Rosa, California

  • ImmunoE Research Center

    Centennial, Colorado

  • Mile High Research Center

    Denver, Colorado

  • Associated Neurologists of Southern Connecticut

    Fairfield, Connecticut

  • Institute for Neurodegenerative Disorders

    New Haven, Connecticut

  • Yale University School Of Medicine

    New Haven, Connecticut

  • Research Center for Clinical Studies, Inc.

    Norwalk, Connecticut

  • Georgetown University Hospital

    Washington D.C., District of Columbia

  • JEM Research Institute

    Atlantis, Florida

  • Bradenton Research Center, Inc.

    Bradenton, Florida

  • Linfritz Research Institute, Inc.

    Coral Gables, Florida

  • Brain Matters Research

    Delray Beach, Florida

  • Neuropsychiatric Research Center of Southwest FL

    Fort Myers, Florida

  • Infinity Clinical Research

    Hollywood, Florida

  • Clincloud, LLC

    Maitland, Florida

  • BioMed Research Institute

    Miami, Florida

  • Finlay Medical Research

    Miami, Florida

  • CCM Clinical Research Group

    Miami, Florida

  • Advance Medical Research Center

    Miami, Florida

  • Advanced Clinical Research Network

    Miami, Florida

  • Gonzalez MD & Aswad MD Health Services

    Miami, Florida

  • Vitae Research Center

    Miami, Florida

  • Miami Jewish Health Systems

    Miami, Florida

  • Allied Biomedical Research (Clinical Trial)

    Miami, Florida

  • Pharmax Research of South Florida, Inc

    Miami, Florida

  • IMIC, Inc.

    Miami, Florida

  • Visionary Investigators Network

    Miami, Florida

  • Visionary Investigators Network

    Miami, Florida

Showing 40 of 247 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.